Clene Inc. (NASDAQ: CLNN), a clinical-stage biopharmaceutical company specializing in neurodegenerative disease treatments, will participate in the upcoming Jones Las Vegas Technology and Innovation Conference on April 8-9, 2025, at The Venetian Resort in Las Vegas, Nevada.
The conference, organized by JonesTrading with marketing support from B2i Digital, Inc., is designed to facilitate meaningful interactions between innovative companies and institutional investors. The event will feature one-on-one meetings, fireside chats, panels, and networking opportunities.
Rob Etherington, CEO and President of Clene, expressed enthusiasm about the conference, highlighting the opportunity to share the company’s progress and connect directly with investors. The event will provide a critical platform for Clene to discuss its innovative approaches to treating conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis.
Notable keynote speakers include Dr. Charity Dean, CEO of PHC Global, and Eric F. Trump, Executive Vice President of The Trump Organization. The conference will also include a Golf Event and Cocktail Reception.
Clene’s participation underscores the company’s commitment to advancing neurological disease treatment through its investigational therapy CNM-Au8®, which focuses on improving mitochondrial health and protecting neuronal function.
The Jones Las Vegas Technology and Innovation Conference represents a significant opportunity for Clene to showcase its scientific advancements and engage with potential investors interested in groundbreaking medical research.
This news story relied on a press release distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Clene to Present at Jones Las Vegas Technology and Innovation Conference.